Le « second look » un concept dépassé?

  • C. Zinzindohoué
  • P. Bertrand
Part of the Abord clinique book series (ONCOLPRAT)


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Santoro BT, Griffen WO, Jr, Wangensteen OH (1961) The second-look procedure in the management of ovarian malignancies and pseudomyxoma peritonei. Surgery 50: 354–8PubMedGoogle Scholar
  2. 2.
    Dowdy SC, Constantinou CL, Hartmann LC et al. (2003) Long-term follow-up of women with ovarian cancer after positive second-look laparotomy. Gynecol Oncol 91(3): 563–8CrossRefPubMedGoogle Scholar
  3. 3.
    Muderspach L, Muggia FM, Conti PS (1996) Second-look laparotomy for stage III epithelial ovarian cancer: rationale and current issues. Cancer Treat Rev 21(6): 499–511PubMedGoogle Scholar
  4. 4.
    Fédération nationale des centres de lutte contre le cancer (1998) La chirurgie de réévaluation ou second look. In: Standards, Options et Recommandations, editor. Tumeurs épithéliales malignes de l’ovaire. Paris: John Libbey Eurotext p 84–8Google Scholar
  5. 5.
    NIH consensus conference (1995) Ovarian cancer. Screening, treatment, and follow-up. NIH Consensus Development Panel on Ovarian Cancer. Jama 273(6): 491–7Google Scholar
  6. 6.
    Tuxen MK, Lund B, Hansen OP et al. (1993) Second-look laparotomy in the management of patients after radical surgery for ovarian cancer. Ann Oncol 4(2): 169–71PubMedGoogle Scholar
  7. 7.
    Ozalp S, Yalcin OT, Dundar E et al. (1999) Second-look laparotomy; factors affecting the results and the prognosis. Eur J Gynaecol Oncol 20(5–6): 398–402PubMedGoogle Scholar
  8. 8.
    Chiara S, Lionetto R, Campora E et al. (1995) Long-term prognosis following macroscopic complete response at second-look laparotomy in advanced ovarian cancer patients treated with platinum-based chemotherapy. The Gruppo Oncologico Nord Ovest. Eur J Cancer 31A(3): 296–301PubMedGoogle Scholar
  9. 9.
    Smith JS, PE (1980) Second look laparotomy and prognosis related to extent of residual disease. In: Progress T, editor. Ovarian Cancer, Testicula Cancer and the Sacromas. the Hague: Martinus Nijhoff p 77–84Google Scholar
  10. 10.
    Soeters RP, Bloch B, Dehaeck K, Levin W. The influence of initial residual disease on the outcome of second-look laparotomy in patients with carcinoma of the ovary. Eur J Gynaecol Oncol 1992; 13(3): 223–7.PubMedGoogle Scholar
  11. 11.
    Chu CS, Rubin SC (2001) Second-look laparotomy for epithelial ovarian cancer: a reappraisal. Curr Oncol Rep 3(1): 11–8PubMedGoogle Scholar
  12. 12.
    Piccart MJ, Floquet A, Scarfone G et al. (2003) Intraperitoneal cisplatin versus no further treatment: 8-year results of EORTC 55875, a randomized phase III study in ovarian cancer patients with a pathologically complete remission after plati-num-based intravenous chemotherapy. Int J Gynecol Cancer 13Suppl 2: 196–203PubMedGoogle Scholar
  13. 13.
    Lawton F, Luesley D, Blackledge G et al. (1990) A randomized trial comparing whole abdominal radiotherapy with chemotherapy following cisplatinum cytoreduction in epithelial ovarian cancer. West Midlands Ovarian Cancer Group Trial II. Clin Oncol (R Coll Radiol) 2(1): 4–9Google Scholar
  14. 14.
    Lambert HE, Rustin GJ, Gregory WM et al. (1993) A randomized trial comparing singleagent carboplatin with carboplatin followed by radiotherapy for advanced ovarian cancer: a North Thames Ovary Group study. J Clin Oncol 11(3): 440–8PubMedGoogle Scholar
  15. 15.
    Goldberg H, Stein ME, Steiner M et al. (2001) Consolidation radiation therapy following cytoreductive surgery, chemotherapy and second-look laparotomy for epithelial ovarian carcinoma: long-term follow-up. Tumori 87(4): 248–51PubMedGoogle Scholar
  16. 16.
    Tournigand C, Louvet C, Molitor JL et al. (2003) Long-term survival with consolidation intraperitoneal chemotherapy for patients with advanced ovarian cancer with pathological complete remission. Gynecol Oncol 91(2): 341–5CrossRefPubMedGoogle Scholar
  17. 17.
    Sijmons EA, Heintz AP (2000) Second-look and second surgery: second chance or second best? Semin Surg Oncol 19(1): 54–61CrossRefPubMedGoogle Scholar
  18. 18.
    Cohen CJ, Goldberg JD, Holland JF et al. (1983) Improved therapy with cisplatin regimens for patients with ovarian carcinoma (FIGO Stages III and IV) as measured by surgical endstaging (second-look operation). Am J Obstet Gynecol 145(8): 955–67PubMedGoogle Scholar
  19. 19.
    Niloff JM, Bast RC, Jr., Schaetzl EM et al. (1985) Predictive value of CA 125 antigen levels in second-look procedures for ovarian cancer. Am J Obstet Gynecol 151(7): 981–6PubMedGoogle Scholar
  20. 20.
    Berek JS, Knapp RC, Malkasian GD et al. (1986) CA 125 serum levels correlated with second-look operations among ovarian cancer patients. Obstet Gynecol 67(5): 685–9PubMedGoogle Scholar
  21. 21.
    Rome RM, Koh H, Fortune D et al. (1987) CA125 serum levels and secondary laparotomy in epithelial ovarian tumours. Aust N Z J Obstet Gynaecol 27(2): 142–5PubMedGoogle Scholar
  22. 22.
    Rubin SC, Hoskins WJ, Hakes TB et al. (1989) Serum CA 125 levels and surgical findings in patients undergoing secondary operations for epithelial ovarian cancer. Am J Obstet Gynecol 160(3): 667–71PubMedGoogle Scholar
  23. 23.
    Murolo C, Costantini S, Foglia G et al. (1989) Ultrasound examination in ovarian cancer patients. A comparison with second look laparotomy. J Ultrasound Med 8(8): 441–3PubMedGoogle Scholar
  24. 24.
    Stehman FB, Calkins AR, Wass JL et al. (1988) A comparison of findings at second-look laparotomy with preoperative computed tomography in patients with ovarian cancer. Gynecol Oncol 29(1): 37–42CrossRefPubMedGoogle Scholar
  25. 25.
    Hoskins WJ, Rubin SC (1991) Surgery in the treatment of patients with advanced ovarian cancer. Semin Oncol 18(3): 213–21PubMedGoogle Scholar
  26. 26.
    Delbeke D, Martin WH (2001) Positron emission tomography imaging in oncology. Radiol Clin North Am 39(5): 883–917CrossRefPubMedGoogle Scholar
  27. 27.
    Picchio M, Sironi S, Messa C et al. (2003) Advanced ovarian carcinoma: usefulness of [(18)F]FDG-PET in combination with CT for lesion detec-tion after primary treatment. Q J Nucl Med 47(2): 77–84PubMedGoogle Scholar
  28. 28.
    Casey MJ, Gupta NC, Muths CK (1994) Experience with positron emission tomography (PET) scans in patients with ovarian cancer. Gynecol Oncol 53(3): 331–8CrossRefPubMedGoogle Scholar
  29. 29.
    Kim S, Chung JK, Kang SB et al. (2004) [18F]FDG PET as a substitute for second-look laparotomy in patients with advanced ovarian carcinoma. Eur J Nucl Med Mol Imaging 31(2): 196–201PubMedGoogle Scholar
  30. 30.
    Nicoletto MO, Tumolo S, Talamini R et al. (1997) Surgical second look in ovarian cancer: a randomized study in patients with laparoscopic complete remission—a Northeastern Oncology Cooperative Group-Ovarian Cancer Cooperative Group Study. J Clin Oncol 15(3): 994–9PubMedGoogle Scholar
  31. 31.
    Potter ME, Hatch KD, Soong SJ et al. (1992) Second-look laparotomy and salvage therapy: a research modality only? Gynecol Oncol 44(1): 3–9CrossRefPubMedGoogle Scholar
  32. 32.
    Luesley D, Lawton F, Blackledge G et al. (1988) Failure of second-look laparotomy to influence survival in epithelial ovarian cancer. Lancet 2(8611): 599–603PubMedGoogle Scholar
  33. 33.
    Chambers SK, Chambers JT, Kohorn EI et al. (1988) Evaluation of the role of second-look surgery in ovarian cancer. Obstet Gynecol 72(3 Pt 1): 404–8PubMedGoogle Scholar
  34. 34.
    Obermair A, Cheuk R, Horwood K et al. (2001) Impact of hemoglobin levels before and during concurrent chemoradiotherapy on the response of treatment in patients with cervical carcinoma: preliminary results. Cancer 92(4): 903–8CrossRefPubMedGoogle Scholar
  35. 35.
    Bertelsen K (1990) Tumor reduction surgery and long-term survival in advanced ovarian cancer: a DACOVA study. Gynecol Oncol 38(2): 203–9CrossRefPubMedGoogle Scholar
  36. 36.
    Schwartz PE, Smith JP (1980) Second-look operations in ovarian cancer. Am J Obstet Gynecol 138(8): 1124–30PubMedGoogle Scholar
  37. 37.
    Lippman SM, Alberts DS, Slymen DJ et al. (1988) Second-look laparotomy in epithelial ovarian carcinoma. Prognostic factors associated with survival duration. Cancer 61(12): 2571–7PubMedGoogle Scholar
  38. 38.
    Hoskins WJ, Rubin SC, Dulaney E et al. (1989) Influence of secondary cytoreduction at the time of second-look laparotomy on the survival of patients with epithelial ovarian carcinoma. Gynecol Oncol 34(3): 365–71CrossRefPubMedGoogle Scholar
  39. 39.
    Williams L, Brunetto VL, Yordan E et al. (1997) Secondary cytoreductive surgery at secondlook laparotomy in advanced ovarian cancer: a Gynecologic Oncology Group Study. Gynecol Oncol 66(2): 171–8CrossRefPubMedGoogle Scholar
  40. 40.
    van der Burg ME, van Lent M, Buyse M et al. (1995) The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med 332(10): 629–34PubMedGoogle Scholar
  41. 41.
    McCreath WA, Chi DS (2004) Surgical cytoreduction in ovarian cancer. Oncology (Huntingt) 18(5): 645–53, discussion 653–4, 656, 658Google Scholar
  42. 42.
    Eisenkop SM, Friedman RL, Spirtos NM (2000) The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma. Cancer 88(1): 144–53CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag France 2006

Authors and Affiliations

  • C. Zinzindohoué
  • P. Bertrand

There are no affiliations available

Personalised recommendations